GlassScriptPhysician profile
Jennifer May
NPI 1295396943
$3,682.06
in general payments reported to CMS, 2019-2025
30 companies · $564 in 2025
The $564 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $660 · 2022: $995 · 2023: $921 · 2024: $542 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,047.67 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $528.81 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $281.42 | 2021-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Glaxosmithkline, LLC. | $260.15 | 2021-2025 | Bexsero, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $259.10 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $195.69 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.65 | 2021-2025 | Jardiance, Stiolto Respimat |
| Abbvie INC. | $150.19 | 2022-2025 | |
| Dexcom, INC. | $105.57 | 2021-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $101.45 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $75.70 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $61.11 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $47.48 | 2021-2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $45.49 | 2023 | Gattex |
| Edwards Lifesciences Corporation | $40.04 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $39.70 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.87 | 2022 | |
| Amgen INC. | $29.87 | 2021-2025 | Repatha, Otezla |
| Exact Sciences Corporation | $23.78 | 2023 | Cologuard Collection Kit |
| Seqirus USA INC | $22.33 | 2024 | Fluad, Flucelvax |
| Astellas Pharma US INC | $21.30 | 2023 | Veozah |
| Axsome Therapeutics, INC. | $20.14 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $18.17 | 2025 | Voquezna |
| Abbott Laboratories | $16.28 | 2024 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $15.74 | 2022 | |
| Boston Scientific Corporation | $15.62 | 2022 | |
| Ardelyx, INC. | $15.05 | 2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.31 | 2023 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $13.43 | 2023 | |
| Organon LLC | $3.95 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.